Area of research
Oncology · Pharmacology
Research interest
Research focused on Pembrolizumab and Urbanization, with related work in Wnt signaling pathway, Gut flora, Agonist. Notable publications include 'A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: The Keystone-001 trial', 'Influence of road network expansion on the landscape ecological risk in the Yangtze River Delta region over the past two decades', and 'A novel TNKS/USP25 inhibitor blocks the Wnt pathway to overcome multi-drug resistance in TNKS-overexpressing colorectal cancer'.
Dietary phytosterol supplementation mitigates renal fibrosis <i>via</i> activating mitophagy and modulating the gut microbiota
PPARγ agonist alleviates sepsis-related liver injury by modulating M1/M2 macrophage polarization via the PPARγ/IκBα/NF-κB pathway
MA04.08 Perioperative Tislelizumab for Resectable Non-small Cell Lung Cancer: Final Analysis of RATIONALE-315
A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: The Keystone-001 trial
Influence of road network expansion on the landscape ecological risk in the Yangtze River Delta region over the past two decades
A novel TNKS/USP25 inhibitor blocks the Wnt pathway to overcome multi-drug resistance in TNKS-overexpressing colorectal cancer
Additional file 2 of Quantifying substantial carcinogenesis of genetic and environmental factors from measurement error in the number of stem cell divisions